First subject enrolled in BioCardia’s Phase III heart failure therapy trial
BioCardia has announced the enrolment of the first subject in the randomised, double-blind, placebo-controlled Phase III CardiAMP heart failure (HF)…
BioCardia has announced the enrolment of the first subject in the randomised, double-blind, placebo-controlled Phase III CardiAMP heart failure (HF)…
Renibus Therapeutics has completed subject enrolment for the randomised Phase III PROTECT trial, assessing RBT-1 (stannic protoporfin/iron sucrose) in minimising…
Narcolepsy is a sleep disorder that specifically affects the rapid eye movement (REM) cycle. Hallmark symptoms of narcolepsy include excessive…
Northwestern University in Illinois, US, has enrolled the first subject in a Phase III trial of Cardiol Therapeutics' drug candidate,…
An independent Data Safety Monitoring Board (DSMB) has recommended the continuation of BioCardia's Phase I/II CardiALLO-HF trial as designed. The…
Give your business an edge with our leading industry insights.
Emory University School of Medicine, US, has commenced subject enrolment for BioCardia’s Phase III CardiAMP HF II trial of CardiAMP…
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were reported in a late-breaker trials session…
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were released from a study by Lincoff…
Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, boosting the company’s stock price.…
A study from the University of Birmingham, UK, has indicated that the use of digoxin could lead to substantial cost…